Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genaissance launches gene test for heart defects:

This article was originally published in Clinica

Executive Summary

Genaissance Pharmaceuticals has launched a pharmacogenomic test for cardiac channelopathies - a broad clinical category that includes Long QT and Brugada Syndromes, two causes of arrhythmia that can result in sudden cardiac death. The CLIA-compliant test can confirm the presence of mutations known to cause cardiac channelopathies; identify family members who have similar mutations; and assist physicians in choosing the most appropriate course of treatment for each patient. It works by detecting genetic mutations in five cardiac ion channel genes. It is expected to provide an improvement to cardiac channelopathies testing using traditional electrocardiograms, which may miss a diagnosis, leaving a patient at risk of a sudden cardiac death, said the New Haven, Connecticut firm.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT058585

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel